Instem Announces Sale of ProvantisTM Laboratory Software to Merck Serono

Instem Announces Sale of ProvantisTM Laboratory Software to Merck Serono

CONSHOHOCKEN, PA - March 26th, 2009 - Instem, a leading provider of early drug development software solutions, is pleased to announce that Merck Serono, a division of Merck KGaA, Darmstadt, Germany, has purchased Instem's software solutions in the framework of introducing a global Toxicology Data Management System. Merck Serono has selected Provantis 8TM for its Research & Development laboratory in Ivrea, Italy and will also be upgrading to Provantis 8TM at its facility in Darmstadt, Germany.

ProvantisTM is a modern, fully integrated software system for single users and global organizations engaged in non-clinical evaluation studies. Orchestrating every facet of preclinical drug safety assessment, ProvantisTM streamlines processes and workflows with straightforward, intuitive functionality for simple and complex studies within a GLP or non-GLP environment.

About Instem
Instem is a world-leading information solutions provider for the Life Sciences - accelerating drug and chemical development by increasing client productivity and enhancing the processes that lead to safer, more effective products. In addition to highly focused departmental and scientific solutions, Instem provides a range of Business Intelligence, Planning, Workflow Management, Dosage Formulation, Document Management and Report Compilation applications.
Operating in a highly fragmented Life Sciences IT market, Instem is one of very few organizations that have developed the financial strength necessary to maintain a global leadership position with established products, while introducing new applications that can deliver the improvements in productivity that clients are aggressively pursuing.

Instem is committed to the exceptional customer experience. For more information on Instem and its solutions, please visit www.instem.com or contact them by email at [email protected].

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.